We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
- Authors
SOBELL, Jeffrey M.; FOLEY, Peter; TOTH, Darryl; MROWIETZ, Ulrich; GIROLOMONI, Giampiero; GONCALVES, Joana; DAY, Robert M.; CHEN, Rongdean; YOSIPOVITCH, Gil
- Abstract
Pruritus and skin discomfort/pain negatively impact health-related quality of life (HRQoL). The effects of apremilast, an oral phosphodiesterase 4 inhibitor, on pruritus, skin discomfort/pain, and patient global assessment of psoriasis disease activity (PgAPDA) were assessed in patients with moderate/severe chronic plaque psoriasis in the phase 3 ESTEEM trials. Significant improvements in pruritus and skin discomfort/pain observed at Week 2 with apremilast versus placebo (both studies, p < 0.0001) were sustained through Week 32. Among apremilast-treated patients, improvements in pruritus visual analog scale (VAS) scores correlated with Dermatology Life Quality Index scores (rs = 0.55 [Week 16]; rs≥ 0.51 [Week 32]; both studies, p < 0.001). PgAPDA correlated with improvements in pruritus (rs≥ 0.56 [Week 16]; rs≥ 0.53 [Week 32]; both studies, p < 0.001) and skin discomfort/pain (rs ≥ 0.54 [Week 16]; rs≥ 0.53 [Week 32]; both studies, p < 0.001) VAS scores. Apremilast provided rapid and sustained improvement in pruritus and skin discomfort/pain, symptoms not typically captured in psoriasis assessments (e.g., PASI) that contribute significantly to patients' disease severity and HRQoL perceptions.
- Subjects
PSORIASIS; QUALITY of life; APREMILAST; VISUAL analog scale; DERMATOLOGY
- Publication
Acta Dermato-Venereologica, 2016, Vol 96, Issue 4, p514
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/00015555-2360